The effect of cocoa, soy, oats and fish oil on metabolic syndrome in rats

Journal of the Science of Food and Agriculture

Volumn 92, Issue 11, 2012, Pages 2349-2357

  Barrios Ramos, Juan P ^a   Garduño Siciliano, Leticia ^a   Loredo, Maria ^b   Chamorro Cevallos, German ^b   Jaramillo Flores, Maria E ^a  

^a INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^b UNIVERSIDAD PANAMERICANA   (Mexico)

Author keywords

Cocoa; Functional foods; Hepatic damage; Metabolic syndrome; Steatosis

Indexed keywords

ANTIOXIDANT; FISH OIL;

ANIMAL; ARTICLE; BLOOD; CACAO; CHEMISTRY; COMPARATIVE STUDY; DIET SUPPLEMENTATION; DIET THERAPY; FATTY LIVER; FUNCTIONAL FOOD; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; LIVER; MALE; METABOLIC SYNDROME X; OAT; PATHOLOGY; PATHOPHYSIOLOGY; PLANT SEED; RANDOMIZATION; RAT; SOYBEAN; WISTAR RAT;

ANIMALS; ANTIOXIDANTS; AVENA SATIVA; CACAO; DIETARY SUPPLEMENTS; FATTY LIVER; FISH OILS; FUNCTIONAL FOOD; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; LIVER; MALE; METABOLIC SYNDROME X; RANDOM ALLOCATION; RATS; RATS, WISTAR; SEEDS; SOY FOODS;

ANIMALIA; AVENA; RATTUS; THEOBROMA CACAO;

EID: 84864024655     PISSN: 00225142     EISSN: 10970010     Source Type: Journal    
DOI: 10.1002/jsfa.5637     Document Type: Article

References (50)

1. Paternina-Caicedo A, Alcalá-Cerra J, Paillier-Gonzales G, Romero-Zarante J, Ángela M and Alvis-Guzmán N, Concordancia de tres definiciones de síndrome metabólico en pacientes hipertensos. Rev Salud Publ 11: 898-908 (2009).
2. Buettner R, Parhofer KG, Woenckhaus M, Wrede CE, Kunz-Schughart LA, Scholmerich J, et al, Defining high-fat diet rat models: metabolic and molecular effects of different fat types. J Mol Endocrinol 36: 485-501 (2006).
3. Uslusoy HS, Nak SG, Gulten M and Biyikli Z, Liver histology according to the presence of metabolic syndrome in nonalcoholic fatty liver disease cases. World J Gastroenterol 15: 1093-1098 (2009).
4. Kuntz E and Dieter-Kuntz H, Hepatology. Textbook and Atlas (3rd edn). Springer, Heidelberg, pp. 593-654 (2008).
5. Basaranoglu M, Kayacetin S, Yilmaz N, Kayacetin E, Tarcin O and Sonsuz A, Understanding mechanisms of the pathogenesis of non-alcoholic fatty liver disease. World J Gastroenterol 16: 2223-2226 (2010).
6. Berge RK, Tronsstaki KJ, Berge K, Rost TH, Wergedahal H, Gudbrandsen OA, et al, The metabolic syndrome and the hepatic fatty acid drainage hypothesis. Biochimie 87: 15-20 (2005).
7. Matsuda H, Chisaka T, Kubomura Y, Yamahara J, Sawada T, Hajime F, et al, Effects of crude drugs on experimental hypercholesterolemia. I. Tea and its active principles. J Ethnopharmacol 17: 213-224 (1986).
8. Wiernsperger N, Geloen A and Rapin JR, Fructose and cardiometabolic disorders: the controversy will, and must, continue. Clinics 65: 729-738 (2010).
9. McGillicuddy FC, De la Llera M, Hinkle CC, Josh MR, Chiquoine EH, Billheimer JT, et al, Inflammation impairs reverse cholesterol transport in vivo. Circulation 119: 1135-1145 (2009).
10. Lye HS, Kuan CY, Ewe JA, Fung WY and Liong MT, The improvement of hypertension by probiotics: effects on cholesterol, diabetes, rennin, and phytoestrogens. Int J Mol Sci 10: 3755-3775 (2009).
11. Fardet A, Rock E and Rémésy C, Is the in vitro antioxidant potential of whole-grain cereals and cereal products well reflected in vivo? J Cereal Sci 48: 258-276 (2008).
12. Liu RH, Whole grain phytochemicals and health. J Cereal Sci 46: 207-219 (2007).
13. Kafui K, Antioxidante activity of grains. J Agric Food Chem 50: 6182-6187 (2002).
14. AOAC, Official Methods of Analysis (17th edn, 1st rev.). AOAC International, Gaithersburg, MD (2001).
15. Martínez R, Castro I and Oliveros M, Characterization of products from sugar cane mud. J Mex Chem Soc 46: 62-66 (2002).
16. Ubaldi A, Delbono G, Fusari A and Serventi P, Quick HPLC method to determine vitamine E concentration in cow's milk. Ann Fac Med Vet Parma XXV: 101-110 (2005).
17. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al, Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313-1321 (2005).
18. Ponnian SMP, Hansi P and Periathambi TD, Gallic acid prevents lysosomal damage in isoproterenol induced cardiotoxicity in Wistar rats. Eur J Pharmacol 615: 139-143 (2009).
19. Lecumberri E, Goya L and Mates R, A diet rich in dietary fiber from cocoa improves lipid profile and reduces malondialdehyde in hypercholesterolemic rats. Nutricion 23: 332-341 (2007).
20. Dewell A, Hollenbeck CB and Bruce B, The effects of soy-derived phyto-estrogens on serum lipids and lipoproteins in moderately hypercholesterolemic postmenopausal women. J Clin Endocrinol Metabol 87: 118-121 (2002).
21. Han KK, Soares JM, Haidar MA, De Lima GR and Baracat EC, Benefits of soy isoflavone therapeutic regimen on menopausal symptoms. Obstet Gynecol 99: 389-394 (2002).
22. Howes JB, Sullivan D, Lai N, Nestel P, Pomeroy S, West L, et al, The effects of dietary supplementation with isoflavones from red clover on the lipoprotein profiles of post menopausal women with mild to moderate hypercholesterolaemia. Atherosclerosis 152: 143-147 (2000).
23. Von Schacky C and Harris WS, Cardiovascular beneficts of omega 3 acids. Cardiovasc Res 73: 310-315 (2007).
24. Surette ME, The science behind dietary omega-3 fatty acids. Can Med Assoc J 178: 177-180 (2008).
25. Ostlund RE, Phytosterols in human nutrition. Annu Rev Nutr 22: 533-549 (2002).
26. Ding EL and Hu FB, Cancer and cholesterol: understanding the V-shaped association in patients with diabetes. Can Med Assoc J 179: 403-404 (2008).
27. Hanhieva K, Törrönen R, Bondi-Pons I, Pekkinen J, Kolehmainen M, Mykkänen H, et al, Impact of dietary polyphenols on carbohydrate metabolism. Int J Mol Sci 11: 1365-1402 (2010).
28. Abbe Maleyki Mhd J, Jahil AMM, Ismail A, Chong PP, Hamid M and Kamaruddin SHS, Effects of cocoa extract containing polyphenols and methylxanthines on biochemical parameters of obese-diabetic rats. J Sci Food Agric 89: 130-137 (2008).
29. Mollace V, Sacco I, Janda E, Malara E, Ventrice D, Colica C, et al, Hypolipemic and hypoglycaemic activity of bergamot polyphenols: from animal models to human studies. Fitoterapia 82: 309-316 (2011).
30. Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan WQ, et al, GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflamatory and insulin-sensitizing effects. Cell 142: 687-698 (2010).
31. Kato M, Miura T, Nakao M, Iwamoto N, Ishida N and Tanigawa K, Effect of alpha-linolenic acid on blood glucose, insulin and GLUT4 protein content of type 2 diabetic mice. J Health Sci 46: 489-492 (2000).
32. Weisburger JH, Chemopreventive effects of cocoa polyphenols on chronic diseases. Exp Biol Med 226: 891-897 (2001).
33. Lamuela-Raventos RM, Covas MI, Fito M, Marrugat J and La Torre-Boronat MC, Detection of dietary antioxidant phenolic compounds in human LDL. Clin Chem 45: 1870-1872 (1999).
34. Lamuela-Raventós RM, Romero-Pérez AI, Andrés-Lacueva C and Tornero A, Health effects of cocoa flavonoids. Food Sci Technol Int 11: 159-176 (2005).
35. Keen CL, Holt RR, Polagruto JA, Wang JF and Schmitz HH, Cocoa flavanols and cardiovascular health. Phytochem Rev 1: 231-240 (2001).
36. Martín L, Sánchez FJ and Vaquero MP, n-3 Fatty acids in glucose metabolism and insulin sensitivity. Nutr Hosp 24: 113-127 (2009).
37. Zhang Y, Jiang L, Hu W, Zheng Q and Xiang W, Mitochondrial dysfunction in in vitro hepatocyte steatosis is reversed by omega-3 fatty acid-induced up-regulation of mitofusin 2. Metabolism 60: 767-775 (2010).
38. Liu Q, Bengmark S and Qu S, The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD). Lipids Health Dis 9: 1-9 (2010).
39. Suzuki A, Lymp J, Sauver J, Angulo P and Lindor K, Values and limitations of serum aminotransferases in clinical trials of nonalcoholic steatohepatitis. Liver Int 26: 1209-1216 (2006).
40. Tetri L, Basaranoglu M, Brunt EM, Yerian LY and Neuschwander-Tetri BA, Severe NFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol 295: 987-995 (2008).
41. Alvarez-Martínez H, Montaño-Estrada LF, Hernández-Cruz P and Pérez-Campos E, Mecanismos moleculares patogénicos en la estetatosis no alcohólica. Rev Gastroenterol Mex 69: 176-183 (2004).
42. Nseir W, Nassar F and Assy N, Soft drinks consumption and nonalcoholic fatty liver disease. World J Gastroenterol 16: 2579-2588 (2010).
43. Angelopoulos TJ, Lowndes J, Melason KJ, Nguyen V, Huffman A and Rippe J, The effect of high-fructose corn syrup consumption on triglycerides and uric acid. J Nutr 139: 1242S-1245S (2009).
44. Bose M, Lambert JD, Ju J, Reuhl KR, Shapses SA and Yang CS, The major green tea polyphenol, (-)-epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat-fed mice. J Nutr 138: 1677-1683 (2008).
45. Carpentier YA, Portois L and Malaisse WJ, n-3 Fatty acids and the metabolic syndrome. Am J Clin Nutr 83: 1499S-1504S (2006).
46. Medina J, García-Buey L, Fernandez-Salazar JI and Moreno-Otero R, Approach to the phathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care 27: 2057-2064 (2004).
47. Nascimento FA, Barbosa-da-Silva S, Fernandes-Santos C, Mandarim-de-Lacerda CA and Aquila MB, Adipose tissue, liver and pancreas structural alterations in C57BL/6 mice fed high-fat-high-sucrose diet supplemented with fish oil (n-3 fatty acid rich oil). Exp Toxicol Pathol 62: 17-25 (2010).
48. Wu LY, Juan CC, Ho LT, Hsu YP and Hwang LS, Effect of green tea supplementation on insulin sensitivity in Sprague-Dawley rats. J Agric Food Chem 52: 643-648 (2004).
49. Molendi-Coste O, Legry V and Leclercq IA, Why and how meet n-3 PUFA dietary recommendations? Gastroenterol Res Pract 2011: 1-11 (2011).
50. Torres-Torres N and Tovar-Palacio AR, La historia del uso de la soya en México, su valor nutricional y su efecto en la salud. Salud Publ Mex 51: 246-254 (2009).